[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100255866":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":27,"locations":35,"responsibleParty":52,"collaborators":17,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":17,"enrollmentInfo":64,"targetDuration":17,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":37,"whyStopped":17,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Active Surveillance","Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.",[12],"Other: Active Surveillance",{"label":14,"type":15,"description":16,"interventionNames":17},"Immediate Surgery","NO_INTERVENTION","Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered \"no intervention\" because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma.",null,[19],{"type":6,"name":9,"description":20,"armGroupLabels":21,"otherNames":17},"Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.",[9],[23],{"name":24,"affiliation":25,"role":26},"Allen Ho, MD","Cedars-Sinal Medical Center","PRINCIPAL_INVESTIGATOR",[28,32],{"name":24,"role":29,"phone":30,"phoneExt":17,"email":31},"CONTACT","310-423-1220","Allen.Ho@cshs.org",{"name":33,"role":29,"phone":17,"phoneExt":17,"email":34},"Clinical Trials Navigator","GroupCancerTrialInformation@cshs.org",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Los Angeles","California","90048","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-118.24368,34.05223,{"lat":47,"lon":46},[50,51],{"name":24,"role":29,"phone":30,"phoneExt":17,"email":31},{"name":24,"role":26,"phone":17,"phoneExt":17,"email":17},{"type":26,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Allen Ho","Director, Head and Neck Cancer Program and Co-Director, Thyroid Cancer Program","100255866","active-surveillance-of-papillary-thyroid-microcarcinoma-100255866",false,"NCT02609685","Active Surveillance of Papillary Thyroid Microcarcinoma","PMCAS","Inclusion Criteria:\n\n* Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.\n* 2.0 cm or smaller nodules by ultrasonographic criteria\n* Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form\n* Must be able to read and write English fluently to participate in the questionnaire portion of the study\n\nExclusion Criteria:\n\n* High-grade or poorly differentiated PTC variants\n* Central or lateral neck lymphadenopathy suspicious for PTC\n* Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)\n* History of radiation to neck","ALL","18 Years",{"count":65,"type":66},216,"ESTIMATED","INTERVENTIONAL",[69],"NA","The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.",[72],"Papillary Thyroid Microcarcinoma",[74,75,76],"Thyroid cancer","Active surveillance","PTMC","2026-05-01",{"date":79,"type":80},"2026-05-07","ACTUAL",{"date":82,"type":80},"2016-05-13",{"date":84,"type":66},"2030-12",{"name":5,"class":6},1]